loading page

Omalizumab treated urticaria patients display T cell and thrombocyte-associated gene regulation
  • +4
  • Anna Smola,
  • Heike Hawerkamp,
  • Peter Oláh,
  • Andreas Kislat,
  • Nicole Duschner,
  • Bernhard Homey,
  • Stephan Meller
Anna Smola
University Hospital of Düsseldorf
Author Profile
Heike Hawerkamp
University Hospital of Düsseldorf

Corresponding Author:heike.hawerkamp@hhu.de

Author Profile
Peter Oláh
University of Pécs
Author Profile
Andreas Kislat
University Hospital of Düsseldorf
Author Profile
Nicole Duschner
University Hospital of Düsseldorf
Author Profile
Bernhard Homey
University Hospital of Düsseldorf
Author Profile
Stephan Meller
University Hospital of Düsseldorf
Author Profile

Abstract

Chronic spontaneous urticaria (CSU) is a debilitating inflammatory skin disease with a prevalence of approximately 1% of the population. It is characterised by recurrent itchy wheals and/or angioedema for more than 6 weeks without known triggers leading to a high quality of life impairment. The pathogenesis of CSU remains not fully understood. This study aimed to explore the pathomechanism of CSU beyond mast cells and IgE-dependent histamine release and to identify possible biomarkers for the disease and its treatment. We investigated a patient cohort in the first month of omalizumab treatment regarding the IgE levels and changes of gene and miRNA expression in peripheral blood. The cohort was divided into responders and non-responders (depending on the score of the Urticaria Control Test) and compared to a group of healthy controls. Our messenger RNA and microRNA microarray analyses revealed the greatest changes of expression levels at day 2 after the first omalizumab dose. We identified several genes and miRNAs of interest, most of which have not been described to be linked to CSU so far, underlining, for example, to T cell involvement or even suggesting platelet involvement.
18 Jul 2024Submitted to Immunity, Inflammation and Disease
06 Aug 2024Submission Checks Completed
06 Aug 2024Assigned to Editor
10 Aug 2024Reviewer(s) Assigned
10 Sep 2024Review(s) Completed, Editorial Evaluation Pending
18 Sep 2024Editorial Decision: Revise Major